Antibiotics: Derivative drugs, novel compounds and the need for effective resistance strategies

Future Microbiology

Volumn 4, Issue 10, 2009, Pages 1243-1247

  Theuretzbacher, Ursula ^a  

^a Center For Anti Infective Agents Vienna   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ACHN 490; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AN 3334; ANTIBIOTIC AGENT; BAL 30072; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE INHIBITOR; CARBAPENEM DERIVATIVE; CEFTAROLINE; CEFTRIAXONE; CEM 101; CXA 101; DAPTOMYCIN; DELAFLOXACIN; EXTENDED SPECTRUM BETA LACTAMASE; FINAFLOXACIN; KETOLIDE; MX 2401; NEMONOXACIN; NITAZOXANIDE; NVB 302; NXL 104; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RADEZOLID; RAZUPENEM; TAZOBACTAM; TETRACYCLINE DERIVATIVE; TOREZOLID; TP 038; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; CLINICAL TRIAL; CLOSTRIDIUM DIFFICILE; COMMUNITY ACQUIRED PNEUMONIA; CONFERENCE PAPER; CROSS RESISTANCE; DRUG APPROVAL; DRUG RESEARCH; HUMAN; INTESTINE INFECTION; LUNG INFECTION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NONHUMAN; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; SKIN INFECTION; SOFT TISSUE INFECTION; VANCOMYCIN RESISTANT ENTEROCOCCUS;

ANTI-BACTERIAL AGENTS; BACTERIA; DRUG DISCOVERY; DRUG RESISTANCE, BACTERIAL; HUMANS; SAN FRANCISCO;

EID: 74749097183     PISSN: 17460913     EISSN: None     Source Type: Journal    
DOI: 10.2217/fmb.09.97     Document Type: Conference Paper

References (20)

1. Woodford N: Emerging antibiotic resistance among Gram-negatives: key pathogens and resistance mechanisms. Presented at: 49th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA, USA, 12-15 September 2009 (Abstract 1861).
2. Durham K, Ge M, Cuccia AJ, Quinn JP: Modeling antibiotic resistance to project future rates: fluoroquinolone resistance in Escherichia coli. Presented at: 49th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA, USA, 12-15 September 2009 (Abstract C2-717).
3. Bonomo RA: Top ten papers in b-lactamases. Presented at: 49th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA, USA, 12-15 September 2009 (Abstract 456).
4. Payne DJ: Lessons learned and future directions. Presented at: 49th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA, USA, 12-15 September 2009 (Abstract 1806).
5. Jabes D, Candiani G, Romano G, Brunati C, Riva S: NAI-107: superior efficacy in animal models of MDR Gram-positive infection. Presented at: 49th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA, USA, 12-15 September 2009 (Abstract F1-1503).
6. Hazra A, Hanna D, Ravva P et al.: Use of a semi-mechanistic PK/PD model for IV sulopenem (S) and sulopenem etzadroxil (SE) dose selection for patients with communityacquired pneumonia (CAP). Presented at: 49th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA, USA, 12-15 September 2009 (Abstract A1-024).
7. Bhavnani SM, Lawrence L, Burak E, Ambrose PG: Clinical trial dose selection for delafloxacin (DFX) for complicated skin and skin-structure infections (cSSSI). Presented at: 49th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA, USA, 12-15 September 2009 (Abstract A1-1942).
8. Bhavnani SM, Lehoux D, Rubino CM et al. Use of pharmacokinetics-pharmacodynamics (PK-PD) to support oritavancin (ORI) dose selection for patients with complicated skin and skin-structure infection (cSSSI): clinical confirmation of proof of concept. Presented at: 49th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA, USA, 12-15 September 2009 (Abstract A1-1288).
9. Kosowska-Shick K, McGhee P, Appelbaum PC: Affinity of ceftaroline and comparator b-lactams to pencillin-binding proteins (PBPs) from Staphylococcus aureus. Presented at: 49th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA, USA, 12-15 September 2009 (Abstract C1-1350).
10. Eckburg P, Friedland HD, Lee J, Llorens L, Critchley IA, Thye D: Focus 1 and 2: randomized, double-blinded, multicenter Phase III trials of the efficacy and safety of ceftaroline (CPT) vs ceftriaxone (CRO) in community-acquired pneumonia (CAP). Presented at: 49th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA, USA, 12-15 September 2009 (Abstract L1-345a).
11. Laing N, Decorby M, Nichol K et al.: Activity of nemonoxacin, an investigational C8-methoxy non-fluorinated quinolone, against pathogens isolated from Canadian hospitals: CANWARD 2007-2008. Presented at: 49th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA, USA, 12-15 September 2009 (Abstract E-1968).
12. Emrich N, Heisig A, Stubbings W, Labischinski H, Heisig P: Antibacterial activity of finafloxacin against isogenic Escherichia coli isolates expressing combinations of defined mechanisms of fluoroquinolone (FQ) resistance. Presented at: 49th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA, USA, 12-15 September 2009 (Abstract C1-1389).
13. Rubinchik E, Pasetka C, Dugourd D: Antimicrobial lipopeptide MX-2401: a novel non-hemolytic analog of amphomycin. Presented at: 49th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA, USA, 12-15 September 2009 (Abstract F1-2024).
14. Mascio C, Townsend K, Cotroneo N, Silverman J: Microbiological characterization of a novel lipopeptide antibiotic with activity in pulmonary surfactant. Presented at: 49th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA, USA, 12-15 September 2009 (Abstract F1-1218).
15. Titelman E, Karlsson I, Ge Y, Giske CG: Activity of CXA-101 (CXA) plus Tazobactam against ESBL-producing E. coli and K. pneumoniae. Presented at: 49th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA, USA, 12-15 September 2009 (Abstract F1-1993).
16. Freund Y, Kimura R, Baker SJ et al.: In vitro activity and In vivo efficacy of (S)-3 (aminomethyl)benzo[c][1,2]oxaborol-1 (3H)-ol hydrochloride compound: a Gram-negative antimicrobial. Presented at: 49th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA, USA, 12-15 September 2009 (Abstract F1-1223a).
17. Ippolito J, Wang D, Chen S: Novel antibiotic classes to treat Gram-negative infections. Presented at: 49th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA, USA, 12-15 September 2009 (Abstract F2-861).
18. Lofland D, O'Brien W, Xiao X, Hunt D, Clark R, Plamondon L: Oral antibacterial activity of a novel pentacycline. Presented at: 49th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA, USA, 12-15 September 2009 (Abstract F1-1219).
19. Goldstein E, Citron D, Sears P, Babakhani F, Gerding D: Comparative fidaxomicin susceptibilities of isolates collected at baseline, failure, and recurrence from patients in a Phase III trial of Clostridium difficile infection (CDI). Presented at: 49th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA, USA, 12-15 September 2009 (Abstract L1-1641).
20. Wadman SN, Appleyard AN, Ayala T et al.: NVB302: a narrow spectrum antibiotic under development for the treatment of Clostridium difficile infection. Presented at: 49th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA, USA, 12-15 September 2009 (Abstract F1-1517).